NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 215 participants.

Also called NCT07018596

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 215 participants (planned count) (from the registry)
Sponsor
Pulse Biosciences, Inc. (from the registry)
Registry
  • NCT NCT07018596
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Czechia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07018596. Allocation not applicable; no masking; primary purpose treatment. Start 2026-04-06 (actual); primary completion 2026-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System
Acronym
NANOPULSE-AF
Condition
Atrial Fibrillation Paroxysmal
Condition
Cardiac Ablation
Condition
Cardiac Arrhythmia
Intervention (Device)
CellFX nsPFA Cardiac Catheter System
Lead sponsor
Pulse Biosciences, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07018596
Content hash
03341638531e766d83c987642e528d69ab651960a25ec70a7e446b7b3041818a